Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Pediatric cerebral malaria (CM) affects more than 3 million children each year killing ~20%
and leaving one third of survivors with long term neurologic and psychiatric sequelae.
Seizures occur commonly with CM and are associated with an increased risk of death and
neuropsychiatric disabilities. In this Malawi-based, dose- escalation, safety and feasibility
study of enteral levetiracetam in pediatric CM, the investigators will lay the groundwork for
future efficacy studies aimed at improving seizure control and ultimately decreasing the
neurologic morbidity of pediatric CM.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)